Skip to content

Safety and Effectiveness Assessment of the MakAir Artificial Ventilator

Interventional, Open, Non-comparative, Multicenter Study to Assess the Safety and Effectiveness of the Use of the MakAir Artificial Ventilator in the Expected Situation of a Shortage of Technical Devices for Invasive Mechanical Ventilation, Linked to the Coronavirus COVID-19

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04475185
Acronym
COVRESP
Enrollment
4
Registered
2020-07-17
Start date
2020-07-20
Completion date
2020-12-19
Last updated
2021-12-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Respiratory Distress Syndrome

Brief summary

The objective of our study is to carry out an evaluation of the safety and the effectiveness of the use of the MakAir respirator as useful supplement in situation of shortage of technical devices of assistance to the mechanical invasive ventilation, related to COVID-19 through a protocol in 3 successive sequences.

Interventions

DEVICEMakAir

MakAir artificial ventilator

Sponsors

Nantes University Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Sequence 1 : * Patient for whom a certificate has been signed by a support person / family member / close relative independent of the sponsor. * Adult * Non-hypoxemic patient (PaO2 / FiO2\> 300) * Patient requiring invasive mechanical ventilation\> 24 hours * Stabilized patient, i.e. not needing an increase in oxygenation for at least 6 hours Sequence 2 : * Patient for whom a certificate of consent has been signed by a support person / family member / close relative independent of the sponsor. * Adult * Patient with mild to moderate Acute respiratory distress syndrome (300\> Pa02 / FiO2\> 100) * Patient requiring invasive mechanical ventilation\> 3 days * Stabilized patient, i.e. having not required an increase in oxygenation for at least 6 hours Sequence3 : * Patient for whom a certificate of consent has been signed by a support person / family member / close relative independent of the sponsor or waiver due to life-threatening emergency. * Adult * Patient with mild to moderate Acute respiratory distress syndrome (PaO2 / FiO2\> 100) or without Acute respiratory distress syndrome * Patient requiring invasive mechanical ventilation for any duration * Situation of shortage among centers investigating technical devices for invasive ventilation to treat all patients

Exclusion criteria

Sequence 1 and sequence 2: * Patient positive or showing signs of Covid-19 infection * Tracheotomized patient * History of pulmonary emphysema or severe to moderate chronic obstructive pulmonary disease * Patient in recovery and withdrawal phase of ventilatory assistance * Pneumothorax or pneumomediastinum * Hemodynamic instability * Intracranial hypertension * Pregnant woman (A urine or blood pregnancy test must be performed for women of childbearing age) * Major protected (guardianship, curatorship and under the protection of justice) * Lack of affiliation to the French social security system * Participation in another interventional clinical trial Sequence3 : * Tracheotomized patient * History of pulmonary emphysema or severe to moderate moderate chronic obstructive pulmonary disease * Patient in recovery and withdrawal phase of ventilatory assistance * Pneumothorax or pneumomediastinum * Hemodynamic instability * Intracranial hypertension * Pregnant woman (A urine or blood pregnancy test must be performed for women of childbearing age) * Major protected (guardianship, curatorship and under the protection of justice) * Lack of affiliation to the French social security system * Participation in another interventional clinical trial on mechanical ventilation

Design outcomes

Primary

MeasureTime frameDescription
Number of dysfunctions24 hours for sequence 1Number of dysfunctions which can lead to or have led to respiratory adverse events or to serious adverse events (SAE)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026